{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:22:27Z","timestamp":1770992547983,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"DOI":"10.7759\/cureus.69129","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:31:33Z","timestamp":1726029093000},"source":"Crossref","is-referenced-by-count":4,"title":["Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches"],"prefix":"10.7759","author":[{"given":"Shradha P","family":"Kakde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maham","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryyam","family":"Liaqat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husnain","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Muaz","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Asad","family":"Sarwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Wali","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Faqeer Hussain","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S32-42. 10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: Definition and subtypes","volume":"29","author":"Han SK","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol. 2023, 29:S5-S16. 10.3350\/cmh.2022.0424","journal-title":"Clin Mol Hepatol"},{"key":"ref3","article-title":"Nonalcoholic steatohepatitis (NASH)","author":"Sharma B","year":"2024","unstructured":"Sharma B, John S. Nonalcoholic steatohepatitis (NASH). StatPearls (ed): StatPearls Publishing, Treasure Island; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease - an evolving view","volume":"22","author":"Lindenmeyer CC","year":"2018","unstructured":"Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease - an evolving view. Clin Liver Dis. 2018, 22:11-21. 10.1016\/j.cld.2017.08.003","journal-title":"Clin Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez E","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015, 149:367-78.e5; quiz e14-5. 10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill W","year":"2014","unstructured":"Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014, 15:8591-638. 10.3390\/ijms15058591","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1515\/mr-2022-0024","article-title":"Challenges and opportunities in nonalcoholic steatohepatitis","volume":"2","author":"Wang X","year":"2022","unstructured":"Wang X. Challenges and opportunities in nonalcoholic steatohepatitis. Med Rev (2021). 2022, 2:328-30. 10.1515\/mr-2022-0024","journal-title":"Med Rev (2021)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0704","article-title":"Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis","volume":"35","author":"Sinakos E","year":"2022","unstructured":"Sinakos E, Liava C, Loomba R. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. Ann Gastroenterol. 2022, 35:213-25. 10.20524\/aog.2022.0704","journal-title":"Ann Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care","volume":"37","author":"Nogueira JP","year":"2024","unstructured":"Nogueira JP, Cusi K. Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care. Diabetes Spectr. 2024, 37:20-8. 10.2337\/dsi23-0013","journal-title":"Diabetes Spectr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano Y","year":"2013","unstructured":"Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013, 48:434-41. 10.1007\/s00535-013-0758-5","journal-title":"J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello M","year":"2021","unstructured":"Cariello M, Piccinin E, Moschetta A. Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH. Cell Mol Gastroenterol Hepatol. 2021, 11:1519-39. 10.1016\/j.jcmgh.2021.01.012","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2020.07.002","article-title":"Acetyl-CoA Carboxylase inhibition as a therapeutic tool in the battle against NASH: hitting more than just one mechanism?","volume":"10","author":"Lambrecht J","year":"2020","unstructured":"Lambrecht J, Tacke F. Acetyl-CoA Carboxylase inhibition as a therapeutic tool in the battle against NASH: hitting more than just one mechanism?. Cell Mol Gastroenterol Hepatol. 2020, 10:859-61. 10.1016\/j.jcmgh.2020.07.002","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen Z","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020, 152:116-41. 10.1016\/j.freeradbiomed.2020.02.025","journal-title":"Free Radic Biol Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04627-0","article-title":"Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions","volume":"21","author":"Myint M","year":"2023","unstructured":"Myint M, Oppedisano F, De Giorgi V, Kim BM, Marincola FM, Alter HJ, Nesci S. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. J Transl Med. 2023, 21:757. 10.1186\/s12967-023-04627-0","journal-title":"J Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/livers2010003","article-title":"Oxidative stress in non-alcoholic fatty liver disease","volume":"2","author":"Smirne C","year":"2022","unstructured":"Smirne C, Croce E, Di Benedetto D, et al.. Oxidative stress in non-alcoholic fatty liver disease. Livers. 2022, 2:30-76. 10.3390\/livers2010003","journal-title":"Livers"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16087","article-title":"Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: A critical pathway molecule worth investigating","volume":"38","author":"Chen Q","year":"2023","unstructured":"Chen Q, Guo J, Qiu T, Zhou J. Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: A critical pathway molecule worth investigating. J Gastroenterol Hepatol. 2023, 38:378-85. 10.1111\/jgh.16087","journal-title":"J Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12091653","article-title":"Oxidative stress in liver pathophysiology and disease","volume":"12","author":"Allameh A","year":"2023","unstructured":"Allameh A, Niayesh-Mehr R, Aliarab A, Sebastiani G, Pantopoulos K. Oxidative stress in liver pathophysiology and disease. Antioxidants (Basel). 2023, 12:10.3390\/antiox12091653","journal-title":"Antioxidants (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada P","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?. Cell Death Dis. 2020, 11:802. 10.1038\/s41419-020-03003-w","journal-title":"Cell Death Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.02.184","article-title":"The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis","volume":"8","author":"M\u00e9ndez-S\u00e1nchez N","year":"2020","unstructured":"M\u00e9ndez-S\u00e1nchez N, Valencia-Rodr\u00edguez A, Coronel-Castillo C, Vera-Barajas A, Contreras-Carmona J, Ponciano-Rodr\u00edguez G, Zamora-Vald\u00e9s D. The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis. Ann Transl Med. 2020, 8:400. 10.21037\/atm.2020.02.184","journal-title":"Ann Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v15.i6.755","article-title":"Treatment of liver fibrosis: Past, current, and future","volume":"15","author":"Zhang CY","year":"2023","unstructured":"Zhang CY, Liu S, Yang M. Treatment of liver fibrosis: Past, current, and future. World J Hepatol. 2023, 15:755-74. 10.4254\/wjh.v15.i6.755","journal-title":"World J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/jpps.2023.11808","article-title":"Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches","volume":"26","author":"Mohammed OS","year":"2023","unstructured":"Mohammed OS, Attia HG, Mohamed BM, Elbaset MA, Fayed HM. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. J Pharm Pharm Sci. 2023, 26:11808. 10.3389\/jpps.2023.11808","journal-title":"J Pharm Pharm Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.09.013","article-title":"Farnesoid X receptor agonists: a promising therapeutic strategy for gastrointestinal diseases","volume":"3","author":"Almeqdadi M","year":"2024","unstructured":"Almeqdadi M, Gordon FD. Farnesoid X receptor agonists: a promising therapeutic strategy for gastrointestinal diseases. Gastro Hep Adv. 2024, 3:344-52. 10.1016\/j.gastha.2023.09.013","journal-title":"Gastro Hep Adv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman RW","year":"2020","unstructured":"Chapman RW, Lynch KD. Obeticholic acid-a new therapy in PBC and NASH. Br Med Bull. 2020, 133:95-104. 10.1093\/bmb\/ldaa006","journal-title":"Br Med Bull"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal AJ","year":"2023","unstructured":"Sanyal AJ, Ratziu V, Loomba R, et al.. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023, 79:1110-20. 10.1016\/j.jhep.2023.07.014","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00318","article-title":"Synthesis and biological evaluation of a series of bile acid derivatives as FXR agonists for treatment of NASH","volume":"8","author":"Xiao H","year":"2017","unstructured":"Xiao H, Li P, Li X, et al.. Synthesis and biological evaluation of a series of bile acid derivatives as FXR agonists for treatment of NASH. ACS Med Chem Lett. 2017, 8:1246-51. 10.1021\/acsmedchemlett.7b00318","journal-title":"ACS Med Chem Lett"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107791","article-title":"Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis","volume":"222","author":"Han X","year":"2021","unstructured":"Han X, Wu Y, Yang Q, Cao G. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. Pharmacol Ther. 2021, 222:107791. 10.1016\/j.pharmthera.2020.107791","journal-title":"Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1723","article-title":"Deuterium\u2010stabilized (R)\u2010pioglitazone (PXL065) Is responsible for pioglitazone efficacy in NASH yet exhibits little to no PPAR\u03b3 activity","volume":"5","author":"Jacques V","year":"2021","unstructured":"Jacques V, Bolze S, Hallakou-Bozec S, et al.. Deuterium\u2010stabilized (R)\u2010pioglitazone (PXL065) Is responsible for pioglitazone efficacy in NASH yet exhibits little to no PPAR\u03b3 activity. Hepatol Commun. 2021, 5:1412-25. 10.1002\/hep4.1723","journal-title":"Hepatol Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084305","article-title":"PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients","volume":"23","author":"Lange NF","year":"2022","unstructured":"Lange NF, Graf V, Caussy C, Dufour JF. PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients. Int J Mol Sci. 2022, 23:10.3390\/ijms23084305","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-579","article-title":"Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease","volume":"11","author":"Yoneda M","year":"2022","unstructured":"Yoneda M, Kobayashi T, Asako N, Iwaki M, Saito S, Nakajima A. Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2022, 11:433-5. 10.21037\/hbsn-21-579","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng HS","year":"2019","unstructured":"Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JY, Tan NS. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence. Int J Mol Sci. 2019, 20:10.3390\/ijms20205055","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022, 39:1233-48. 10.1007\/s11095-022-03302-1","journal-title":"Pharm Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim G","year":"2023","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023, 19:60-70. 10.17925\/EE.2023.19.1.60","journal-title":"touchREV Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison SA","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al.. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023, 29:2919-28. 10.1038\/s41591-023-02603-1","journal-title":"Nat Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri N","year":"2020","unstructured":"Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020, 29:135-41. 10.1080\/13543784.2020.1668374","journal-title":"Expert Opin Investig Drugs"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59101789","article-title":"Potential therapeutic strategies in the treatment of metabolic-associated fatty liver disease","volume":"59","author":"Bo\u0142dys A","year":"2023","unstructured":"Bo\u0142dys A, Bu\u0142dak \u0141, Malig\u0142\u00f3wka M, Surma S, Okopie\u0144 B. Potential therapeutic strategies in the treatment of metabolic-associated fatty liver disease. Medicina (Kaunas). 2023, 59:10.3390\/medicina59101789","journal-title":"Medicina (Kaunas)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2020.016","article-title":"Selonsertib inhibits liver fibrosis via downregulation of ASK1\/MAPK pathway of hepatic stellate cells","volume":"28","author":"Yoon YC","year":"2020","unstructured":"Yoon YC, Fang Z, Lee JE, Park JH, Ryu JK, Jung KH, Hong SS. Selonsertib inhibits liver fibrosis via downregulation of ASK1\/MAPK pathway of hepatic stellate cells. Biomol Ther (Seoul). 2020, 28:527-36. 10.4062\/biomolther.2020.016","journal-title":"Biomol Ther (Seoul)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR\u00a0trials","volume":"73","author":"Harrison SA","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, et al.. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR\u00a0trials. J Hepatol. 2020, 73:26-39. 10.1016\/j.jhep.2020.02.027","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: Insights from clinical trials and error","volume":"78","author":"Ratziu V","year":"2023","unstructured":"Ratziu V, Charlton M. Rational combination therapy for NASH: Insights from clinical trials and error. J Hepatol. 2023, 78:1073-9. 10.1016\/j.jhep.2022.12.025","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071166","article-title":"Combination therapies for nonalcoholic fatty liver disease","volume":"12","author":"Makri ES","year":"2022","unstructured":"Makri ES, Makri E, Polyzos SA. Combination therapies for nonalcoholic fatty liver disease. J Pers Med. 2022, 12:10.3390\/jpm12071166","journal-title":"J Pers Med"},{"key":"ref40","article-title":"The emerging role of bariatric surgery in the management of nonalcoholic fatty liver disease","author":"Lin J","year":"2024","unstructured":"Lin J, Gulati A. The emerging role of bariatric surgery in the management of nonalcoholic fatty liver disease. StatPearls (ed): StatPearls Publishing, Treasure Island; 2024."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173783","article-title":"Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: a 12-month follow-up study with paired liver biopsies","volume":"10","author":"Pedersen JS","year":"2021","unstructured":"Pedersen JS, Rygg MO, Serizawa RR, et al.. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: a 12-month follow-up study with paired liver biopsies. J Clin Med. 2021, 10:10.3390\/jcm10173783","journal-title":"J Clin Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/839275","article-title":"Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?","volume":"2013","author":"Hafeez S","year":"2013","unstructured":"Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?. J Obes. 2013, 2013:839275. 10.1155\/2013\/839275","journal-title":"J Obes"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1026444","article-title":"Bariatric endoscopic-surgical therapies for NAFLD. Should they be considered viable options among current treatments?","volume":"13","author":"Ju\u00e1rez-Hern\u00e1ndez E","year":"2022","unstructured":"Ju\u00e1rez-Hern\u00e1ndez E, Vel\u00e1zquez-Alem\u00e1n AP, Castro-Narro G, Uribe M, L\u00f3pez-M\u00e9ndez I. Bariatric endoscopic-surgical therapies for NAFLD. Should they be considered viable options among current treatments?. Front Endocrinol (Lausanne). 2022, 13:1026444. 10.3389\/fendo.2022.1026444","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. The","volume":"401","author":"Verrastro O","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, et al.. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. The. Lancet. 2023, 401:1786-97. 10.1016\/S0140-6736(23)00634-7","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04644-8","article-title":"Intragastric balloon versus endoscopic sleeve gastroplasty for the treatment of obesity: a systematic review and meta-analysis","volume":"30","author":"Singh S","year":"2020","unstructured":"Singh S, de Moura DT, Khan A, et al.. Intragastric balloon versus endoscopic sleeve gastroplasty for the treatment of obesity: a systematic review and meta-analysis. Obes Surg. 2020, 30:3010-29. 10.1007\/s11695-020-04644-8","journal-title":"Obes Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05695-7","article-title":"Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)","volume":"22","author":"Lav\u00edn-Alconero L","year":"2021","unstructured":"Lav\u00edn-Alconero L, Fern\u00e1ndez-Lanas T, Iruzubieta-Coz P, et al.. Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). Trials. 2021, 22:756. 10.1186\/s13063-021-05695-7","journal-title":"Trials"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2017.04.022","article-title":"Behavioral lifestyle interventions for moderate and severe obesity: A systematic review","volume":"100","author":"Lv N","year":"2017","unstructured":"Lv N, Azar KM, Rosas LG, Wulfovich S, Xiao L, Ma J. Behavioral lifestyle interventions for moderate and severe obesity: A systematic review. Prev Med. 2017, 100:180-93. 10.1016\/j.ypmed.2017.04.022","journal-title":"Prev Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i16.2041","article-title":"Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Whitsett M","year":"2015","unstructured":"Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. World J Hepatol. 2015, 7:2041-52. 10.4254\/wjh.v7.i16.2041","journal-title":"World J Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth K","year":"2011","unstructured":"Hallsworth K, Fattakhova G, Hollingsworth KG, et al.. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011, 60:1278-83. 10.1136\/gut.2011.242073","journal-title":"Gut"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab795","article-title":"The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis","volume":"107","author":"Sabag A","year":"2022","unstructured":"Sabag A, Barr L, Armour M, et al.. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022, 107:862-81. 10.1210\/clinem\/dgab795","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2015.09.006","article-title":"High intensity interval training improves liver and adipose tissue insulin sensitivity","volume":"4","author":"Marcinko K","year":"2015","unstructured":"Marcinko K, Sikkema SR, Samaan MC, Kemp BE, Fullerton MD, Steinberg GR. High intensity interval training improves liver and adipose tissue insulin sensitivity. Mol Metab. 2015, 4:903-15. 10.1016\/j.molmet.2015.09.006","journal-title":"Mol Metab"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076123","article-title":"Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease","volume":"24","author":"Del Barrio M","year":"2023","unstructured":"Del Barrio M, Lav\u00edn L, Santos-Laso \u00c1, et al.. Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease. Int J Mol Sci. 2023, 24:10.3390\/ijms24076123","journal-title":"Int J Mol Sci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2020.134","article-title":"Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease","volume":"7","author":"Zhou J","year":"2021","unstructured":"Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res. 2021, 7:11. 10.20517\/2394-5079.2020.134","journal-title":"Hepatoma Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1170","article-title":"NASH and the gut microbiome: implications for new therapies","volume":"19","author":"Tsay CJ","year":"2022","unstructured":"Tsay CJ, Lim JK. NASH and the gut microbiome: implications for new therapies. Clin Liver Dis (Hoboken). 2022, 19:97-100. 10.1002\/cld.1170","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour JF","year":"2022","unstructured":"Dufour JF, Anstee QM, Bugianesi E, et al.. Current therapies and new developments in NASH. Gut. 2022, 71:2123-34. 10.1136\/gutjnl-2021-326874","journal-title":"Gut"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00832-z","article-title":"NASH: regulatory considerations for clinical drug development and U.S. FDA approval","volume":"43","author":"Harvey BE","year":"2022","unstructured":"Harvey BE. NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin. 2022, 43:1210-4. 10.1038\/s41401-021-00832-z","journal-title":"Acta Pharmacol Sin"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15438","article-title":"Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20\u2009years of follow-up","volume":"42","author":"Holmer M","year":"2022","unstructured":"Holmer M, Ekstedt M, Nasr P, et al.. Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20\u2009years of follow-up. Liver Int. 2022, 42:2769-80. 10.1111\/liv.15438","journal-title":"Liver Int"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla VA","year":"2020","unstructured":"Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020, 9:10.3390\/cells9041005","journal-title":"Cells"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4228321","article-title":"Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on nonalcoholic fatty liver disease","volume":"2023","author":"Tan HC","year":"2023","unstructured":"Tan HC, Shumbayawonda E, Beyer C, et al.. Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on nonalcoholic fatty liver disease. Int J Biomed Imaging. 2023, 2023:4228321. 10.1155\/2023\/4228321","journal-title":"Int J Biomed Imaging"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50176","article-title":"Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit KK","year":"2023","unstructured":"Adhit KK, Wanjari A, Menon S, K S. Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. Cureus. 2023, 15:e50176. 10.7759\/cureus.50176","journal-title":"Cureus"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/s23239498","article-title":"The emergence of AI-based wearable sensors for digital health technology: a review","volume":"23","author":"Shajari S","year":"2023","unstructured":"Shajari S, Kuruvinashetti K, Komeili A, Sundararaj U. The emergence of AI-based wearable sensors for digital health technology: a review. Sensors (Basel). 2023, 23:10.3390\/s23239498","journal-title":"Sensors (Basel)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/259461","article-title":"Stem cell-based therapies for liver diseases: state of the art and new perspectives","volume":"2010","author":"Piscaglia AC","year":"2010","unstructured":"Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int. 2010, 2010:259461. 10.4061\/2010\/259461","journal-title":"Stem Cells Int"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3945672","article-title":"Mesenchymal stem cells for liver regeneration in liver failure: from experimental models to clinical trials","volume":"2019","author":"de Miguel MP","year":"2019","unstructured":"de Miguel MP, Prieto I, Moratilla A, Arias J, Aller MA. Mesenchymal stem cells for liver regeneration in liver failure: from experimental models to clinical trials. Stem Cells Int. 2019, 2019:3945672. 10.1155\/2019\/3945672","journal-title":"Stem Cells Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/284043-emerging-therapies-for-non-alcoholic-steatohepatitis-nash-a-comprehensive-review-of-pharmacological-and-non-pharmacological-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:31:37Z","timestamp":1726029097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/284043-emerging-therapies-for-non-alcoholic-steatohepatitis-nash-a-comprehensive-review-of-pharmacological-and-non-pharmacological-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.69129","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}